Skip to main content

European (euro) network for development of novel safe vaccines based on new generation amplicons (amp) and other defective hsv-1 derived vectors as foreign antigen delivery systems.

Objective

Seven European laboratories have associated to evaluate the potential of defective HSV vectors, including helper-free HSV amplicons, as vaccine for the delivery of foreign antigens. The model antigens will be derived from human viruses of high public health concern, such as HCV, HIV-1 and HPV-16, each causing significant morbidity and mortality and substantial economic burden. No effective vaccines are available to prevent or treat these viral infections. To this end we plan to determine the conditions required to optimise delivery, expression and presentation of foreign antigens, including the in vivo synthesis of empty virus-like HCV and HPV-16 particles. Significant innovations will be the use of a unique in its nature vector (the amplicon), never used before, as vaccine vector and the attempt to manipulate the immune response by attracting monocytes to sites of infection and inducing their differentiation into dendritic cells.

Funding Scheme

CSC - Cost-sharing contracts

Coordinator

UNIVERSITE CLAUDE BERNARD LYON 1
Address
43,Boulevard Du 11 Novembre 1918, 43
69622 Villeurbanne
France

Participants (5)

GERMAN CANCER RESEARCH CENTER
Germany
Address
242,Im Neuenheimer Feld 242
69120 Heidelberg
HELLENIC PASTEUR INSTITUTE
Greece
Address
127,Vassilissis Sofias Avenue 127
11521 Athens
LUDWIG-MAXIMILIANS UNIVERSITY OF MUNICH
Germany
Address
Geschwister-scholl-platz 1
80539 Muenchen
THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD
United Kingdom
Address
John Radcliffe Hospital
OX3 9DU Oxford
UNIVERSITÀ DEGLI STUDI DI FERRARA
Italy
Address
Via Luigi Borsari 46
44100 Ferrara